跳至主要内容
临床试验/NCT03062150
NCT03062150已完成不适用

Effects of Mineralocorticoid Receptor Stimulation on Cognitive Bias and Social Cognition in Patients With Major Depression and Healthy Controls: What's the Role of NMDA Receptors?

Charite University, Berlin, Germany1 个研究点 分布在 1 个国家目标入组 232 人开始时间: 2016年9月27日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
232
试验地点
1
主要终点
Emotional dot probe

研究概览

简要总结

The steroid hormone cortisol is released in response to stress and acts in the central nervous system upon glucocorticoid (GR) and mineralocorticoid receptors (MR). GR are widely distributed across the brain while MR are predominantly expressed in the hippocampus and prefrontal cortex - two brain areas closely related to memory and executive function. Stimulation of MR leads to an increase of glutamate that act on glutamatergic NMDA receptors in the hippocampus and prefrontal cortex. In previous studies, the investigators have shown that fludrocortisone, a mineralocorticoid receptor (MR) agonist, improves memory and executive function in depressed patients and healthy controls. However, depressed patients not only exhibit cognitive deficits in traditional neuropsychological domains such as memory or executive function. In addition, there are depression-specific alterations such as cognitive bias and deficits in social cognition, two clinically highly relevant areas. Therefore, the specific aims of this renewal proposal are two-fold:

  • To examine whether beneficial effects of fludrocortisone in depressed patients can be extended to depression-specific cognitive bias and to social cognition
  • To determine whether beneficial effects of fludrocortisone depend on NMDA-receptor function and whether these beneficial effects can be enhanced by NMDA receptor stimulation.

The investigators hypothesize that fludrocortisone will improve cognitive bias and social cognition in depressed patients and that its beneficial effects depend on the NMDA receptor. Therefore, the investigators further hypothesize that the effects of fludrocortisone can be enhanced by co-administration of the partial NMDA receptor agonist D-cycloserine.

The study not only advances current knowledge by further examining the mechanism of action by which MR stimulation exerts beneficial effects on cognition but extends these effects to depression-specific cognitive bias and alterations in social cognition. Furthermore, a potential interaction between MR and NMDA receptors is highly clinically relevant given the promising results with NMDA receptor antagonists in the treatment of major depression.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18-65 years
  • Depressed male and female patients according to DSM-V & minimum of 17-items Hamilton Depression Score of 18
  • healthy controls
  • informed consent signed

排除标准

  • Current use of antidepressants, antipsychotics, or mood stabilizer
  • Relevant medical or neurological disorders
  • Pregnancy or unsure contraception
  • Relevant psychiatric comorbidity (bipolar or psychotic disorders)
  • Active alcohol or other substance abuse/dependance

研究组 & 干预措施

Placebo+Placebo

Placebo Comparator

Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.

干预措施: Placebo (Drug)

Fludrocortisone+Placebo

Active Comparator

Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH

Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.

干预措施: Placebo (Drug)

Fludrocortisone+Placebo

Active Comparator

Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH

Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.

干预措施: Fludrocortisone (Drug)

Placebo+D-Cycloserine

Active Comparator

Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.

D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd

干预措施: Placebo (Drug)

Placebo+D-Cycloserine

Active Comparator

Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.

D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd

干预措施: D-Cycloserine (Drug)

Fludrocortison+D-Cycloserine

Active Comparator

Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH

D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd

干预措施: Fludrocortisone (Drug)

Fludrocortison+D-Cycloserine

Active Comparator

Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH

D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd

干预措施: D-Cycloserine (Drug)

结局指标

主要结局

Emotional dot probe

时间窗: 1 hour

In this task, two stimuli (each a photography of a face) are presented quickly on a computer screen (500 ms), and one face stimulus is replaced by a probe (1100 ms). Face pictures can show a sad, happy or neutral expression and are paired as neutralneutral, neutral-sad, or neutral-happy. Participants respond as fast as possible by pressing a key to correspond to the location of the probe. Attentional bias can be derived by the average reaction time when the probe replaces negative stimuli (sad faces), the average reaction time when the probe replaces neutral stimuli (neutral faces), and the average reaction time of positive (happy faces) and neutral stimuli (neutral faces).

次要结局

  • Virtual Water Maze(1 hour)
  • Facial recognition task(1 hour)
  • Multifaceted Empathy Test (MET)(1 hour)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Prof. Dr. Christian Otte

Professor of Psychiatry

Charite University, Berlin, Germany

研究点 (1)

Loading locations...

相似试验